Patient and HCP Preference for a New Epinephrine Nasal Delivery Device

Patient and HCP preference for a new epinephrine nasal delivery device

Written by: Erin Pohl

Imagine the moment when a child has an allergic reaction and starts gasping for air because their throat is closing. The parent then has to find the life-saving medication and give it quickly and accurately to the child who may or may not be willing. This moment can happen anywhere and at anytime.

The standard treatment for anaphylactic shock is epinephrine which is currently delivered via autoinjectors and syringes. To overcome known usability issues with epinephrine injectors like the EpiPen®️, Bryn Pharma, LLC is looking into a new route and device to deliver epinephrine-- the BiDose Epinephrine Nasal Spray. This new nasal spray device provides two intranasal sprays that are absorbed immediately through the mucous membranes in the nose to counteract anaphylaxis.

Earlier this year, Core Human Factors teamed up with Bryn Pharma to investigate users’ preferences between the BiDose Epinephrine Nasal Spray and the EpiPen from three user groups including patients, lay caregivers, and healthcare professionals (HCPs). Participants were asked questions about their preference between the devices in terms of device size, ease of use, portability, perceived safety, likelihood of use during an emergency situation, likelihood of recommending to others, comfort of use in a public setting, and overall preference. The study revealed that the BiDose Epinephrine Nasal Spray was preferred at a significantly higher rate statistically than that of the EpiPen overall and was perceived as easier to use. Due to the exciting nature of the results of the preference study, Core recently presented the HCP arm of this study at the American College of Allergy, Asthma & Immunology National Conference in Houston, TX in November 2019 and the pediatric and lay caregiver arm at the American Academy of Pediatrics (AAP) National Conference in New Orleans, LA in October 2019. For more information about the study and the conference presentations, see the links below.

Link to P005 MULTICENTER, RANDOMIZED CROSSOVER HEALTHCARE PROFESSIONAL PREFERENCE STUDY OF BIDOSE EPINEPHRINE NASAL SPRAY VERSUS EPINEPHRINE AUTOINJECTOR

For more information about the presentation at American Academy of Pediatrics (AAP) National Conference in New Orleans, LA click here: OCTOBER 25–29, 2019 • NEW ORLEANS

Note, Jennifer Soosaar, PhD is listed as the presenting author with additional author credit including Seda Japp, PhD, Sarah Johnstone, MA, Steven Rybicki, MSE, Erin Pohl, MS, Sarah Fairchild, PhD, Patricia Anderson, MSE, and Adam Shames, MBA.